Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 GSK's Rotarix BLA Accepted for Review | Contract Pharma

What are you searching for?

Sign in
Breaking News, Trials & Filings

GSK’s Rotarix BLA Accepted for Review

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

The FDA has accepted for review GlaxoSmithKline’s BLA for Rotarix, an oral candidate vaccine for infants to prevent rotavirus gastroenteritis. If approved, the GSK candidate vaccine could offer completion of the rotavirus vaccination series by four months of age. The rotavirus candidate vaccine is a live-attenuated vaccine derived from the most common human rotavirus strain.

The BLA for the rotavirus candidate vaccine includes data from clinical trials conducted in the Americas, Europe, Asia and Africa in nearly 75,000 infants.

The Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP), the American Academy of Pediatrics (AAP), and the American Academy of Family Physicians (AAFP) recommend that infants receive routine vaccination against rotavirus to prevent rotavirus gastroenteritis with the vaccine currently licensed by the FDA at two, four, and six months of age.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics